---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010399"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:39:42.063989+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock Q2 loss $110M; apitegromab PDUFA Sept 22, 2025; positive EMBRAZE lean mass data

## Summary
- FDA accepted apitegromab BLA under priority review; PDUFA target action date September 22, 2025.
- Phase 2 EMBRAZE trial: apitegromab + tirzepatide preserved 54.9% more lean mass vs tirzepatide alone (p=0.001).
- Q2 net loss $110M ($0.98/shr) vs $58.5M ($0.60/shr) in prior year; no revenue.
- Cash $295M as of June 30, 2025; expected to fund operations into 2027.
- Preparing for U.S. commercial launch upon potential approval; EMA MAA validated, EU launch anticipated 2026.

## SEC filing metadata
- accession: 0001558370-25-010399
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/0001558370-25-010399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010399
- JSON: https://secwatch.observer/filing/0001558370-25-010399.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010399.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.